Standard-risk medulloblastoma Radiotherapy combined with multidrug chemotherapy reduced the prophylactic dose of radiotherapy (usually 24 Gy instead of 35 Gy for whole cranial and whole spinal cord), while maintaining a good 5-year survival rate (75-80%). High-risk medulloblastoma The administration of chemotherapy during and after radiotherapy improved survival but remained below 50%. A method that is still being evaluated is the trial of high-dose chemotherapy prior to radiotherapy with peripheral blood stem cell transplantation. In older children receiving total cranial and total spinal cord irradiation, most recurrences occur mostly in the first 3 years after diagnosis, but later recurrences are possible. They can be localized, single metastases or spread. The prognosis for these recurrences is very serious. Partial or complete regression can often be obtained with rechemotherapy, but cure is usually more rare.